AM-679 (cannabinoid)

AM-679 is a drug which acts as a moderately potent agonist for the cannabinoid receptors, with a K_i of 13.5nM at CB₁ and 49.5nM at CB₂.^[1] AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives that was found to have significant cannabinoid receptor affinity, and while AM-679 itself has only modest affinity for these receptors, it was subsequently used as a base to develop several more specialised cannabinoid ligands which are now widely used in research, including the potent CB₁ agonists AM-694 and AM-2233, and the selective CB₂ agonist AM-1241.^[2] AM-679 was first identified as having been sold as a cannabinoid designer drug in Hungary in 2011, along with another novel compound 1-pentyl-3-(1-adamantoyl)indole.^[3]

See also

• RCS-4
• AM-694
• AM-2233

References

1. ^ WO patent 200128557, Makriyannis A, Deng H, "Cannabimimetic indole derivatives", granted 2001-06-07  
2. ^ Hongfeng Deng. Design and synthesis of selective cannabinoid receptor ligands: Aminoalkylindole and other heterocyclic analogs. PhD Dissertation, University of Connecticut, 2000.
3. ^ Jankovics P, Váradi A, Tölgyesi L, Lohner S, Németh-Palotás J, Balla J (August 2011). "Detection and identification of the new potential synthetic cannabinoids 1-pentyl-3-(2-iodobenzoyl)indole and 1-pentyl-3-(1-adamantoyl)indole in seized bulk powders in Hungary". Forensic Science International. doi:10.1016/j.forsciint.2011.07.011. PMID 21813254.